AIM ImmunoTech (AIM) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,082,275

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 29,759	$ 32,093
Marketable securities	6,986	16,175
Funds receivable from New Jersey net operating loss		1,641
Prepaid expenses and other current assets	805	304
Assets held for sale	3,600
Total current assets	41,150	50,213
Property and equipment, net	118	4,047
Right of use asset, net	866	149
Patent and trademark rights, net	2,013	1,974
Other assets	2,138	1,316
Total assets	46,285	57,699
Current liabilities:
Accounts payable	957	198
Accrued expenses	1,767	438
Current portion of operating lease liability	171	37
Total current liabilities	2,895	673
Long-term liabilities:
Operating lease liability	695	112
Redeemable warrants		35
Commitments and contingencies (Notes 12, 13, and 14)
Stockholders’ equity:
Series B Convertible Preferred Stock, stated value $1,000 per share, 713 and 715 issued and outstanding, respectively	713	715
Common Stock, par value $0.001 per share, authorized 350,000,000 shares: 48,082,275, and 47,994,672, issued and outstanding, respectively	48	48
Additional paid-in capital	418,091	417,217
Accumulated deficit	(376,157)	(361,101)
Total stockholders’ equity	42,695	56,879
Total liabilities and stockholders’ equity	$ 46,285	$ 57,699

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	48,082,275	47,994,672
Common stock, shares outstanding	48,082,275	47,994,672
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock, shares, issued	713	715
Preferred stock, shares, outstanding	713	715

Consolidated Statement of Opera

Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Clinical treatment programs - US	$ 21	$ 33	$ 85	$ 85
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember	AIM:ClinicalTreatmentProgramsUSMember
Costs and Expenses:
Production costs		$ 157		$ 674
Research and development	1,372	2,006	4,883	4,749
General and administrative	5,170	1,799	9,569	6,055
Total Costs and Expenses	6,542	3,962	14,452	11,478
Operating loss	(6,521)	(3,929)	(14,367)	(11,393)
Loss on investments	(365)		(1,769)
Interest and other income, net	172	(20)	296	100
Interest expense and other finance costs				(67)
Extinguishment of financing obligation and note payable				(2,701)
Gain on sale of fixed assets				216
Redeemable warrants valuation adjustment	1	51	35	22
Gain from sale of income tax operating losses	328	72	749	542
Net Loss	(6,385)	(3,826)	(15,056)	(13,281)
Other comprehensive (loss), net of tax
Reclassification adjustment for realized investment loss		101		126
Change in unrealized loss on marketable securities available for sale		(104)		(329)
Comprehensive loss	$ (6,385)	$ (3,829)	$ (15,056)	$ (13,484)
Basic and diluted loss per share	$ (0.13)	$ (0.08)	$ (0.31)	$ (0.28)
Weighted average shares outstanding basic and diluted	48,079,210	47,846,074	48,036,559	47,156,158

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 732	$ 42	$ 402,541	$ (47)	$ (341,974)	$ 61,294
Beginning balance, shares at Dec. 31, 2020		42,154,371
Equity-based compensation			526			526
Net Comprehensive loss				(163)	(3,579)	(3,742)
Common stock issuances, net of costs		$ 6	12,881			12,887
Common stock issuance, net of costs, shares		5,678,626
Series B preferred shares converted to common shares	(7)		7
Ending balance, value at Mar. 31, 2021	725	$ 48	415,955	(210)	(345,553)	70,965
Ending balance. shares at Mar. 31, 2021		47,832,997
Beginning balance, value at Dec. 31, 2020	732	$ 42	402,541	(47)	(341,974)	61,294
Beginning balance, shares at Dec. 31, 2020		42,154,371
Net Comprehensive loss						(13,484)
Ending balance, value at Sep. 30, 2021	725	$ 48	416,779	(250)	(355,255)	62,047
Ending balance. shares at Sep. 30, 2021		47,848,622
Beginning balance, value at Dec. 31, 2020	732	$ 42	402,541	(47)	(341,974)	61,294
Beginning balance, shares at Dec. 31, 2020		42,154,371
Ending balance, value at Dec. 31, 2021	715	$ 48	417,217		(361,101)	56,879
Ending balance. shares at Dec. 31, 2021		47,994,672
Beginning balance, value at Mar. 31, 2021	725	$ 48	415,955	(210)	(345,553)	70,965
Beginning balance, shares at Mar. 31, 2021		47,832,997
Equity-based compensation			480			480
Net Comprehensive loss				(37)	(5,876)	(5,913)
Ending balance, value at Jun. 30, 2021	725	$ 48	416,435	(247)	(351,429)	65,532
Ending balance. shares at Jun. 30, 2021		47,832,997
Equity-based compensation			314			314
Net Comprehensive loss				(3)	(3,826)	(3,829)
Common stock issuances, net of costs			30			30
Common stock issuance, net of costs, shares		15,625
Ending balance, value at Sep. 30, 2021	725	$ 48	416,779	(250)	(355,255)	62,047
Ending balance. shares at Sep. 30, 2021		47,848,622
Beginning balance, value at Dec. 31, 2021	715	$ 48	417,217		(361,101)	56,879
Beginning balance, shares at Dec. 31, 2021		47,994,672
Equity-based compensation			242			242
Net Comprehensive loss					(3,820)	(3,820)
Ending balance, value at Mar. 31, 2022	715	$ 48	417,459		(364,921)	53,301
Ending balance. shares at Mar. 31, 2022		47,994,672
Beginning balance, value at Dec. 31, 2021	715	$ 48	417,217		(361,101)	56,879
Beginning balance, shares at Dec. 31, 2021		47,994,672
Net Comprehensive loss						(15,056)
Ending balance, value at Sep. 30, 2022	713	$ 48	418,091		(376,157)	42,695
Ending balance. shares at Sep. 30, 2022		48,082,275
Beginning balance, value at Mar. 31, 2022	715	$ 48	417,459		(364,921)	53,301
Beginning balance, shares at Mar. 31, 2022		47,994,672
Equity-based compensation			275			275
Net Comprehensive loss					(4,851)	(4,851)
Common stock issuances, net of costs			55			55
Common stock issuance, net of costs, shares		54,150
Series B preferred shares converted to common shares	(2)		2
Ending balance, value at Jun. 30, 2022	713	$ 48	417,791		(369,772)	48,780
Ending balance. shares at Jun. 30, 2022		48,048,822
Equity-based compensation			275			275
Net Comprehensive loss					(6,385)	(6,385)
Common stock issuances, net of costs			25			25
Common stock issuance, net of costs, shares		32,895
Cashless Warrant Conversion
Cashless Warrant share Conversion, shares		558
Ending balance, value at Sep. 30, 2022	$ 713	$ 48	$ 418,091		$ (376,157)	$ 42,695
Ending balance. shares at Sep. 30, 2022		48,082,275

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (6,385)	$ (3,826)	$ (15,056)	$ (13,281)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment			29	484
Redeemable warrants valuation adjustment			(35)	(22)
Extinguishment of financing obligation and note payable				2,701
Amortization of patent, trademark rights			57	97	$ 116
Changes in ROU assets			(717)	35
Gain on sale of property and equipment				(216)
Gain from sale of income tax operating losses			(749)	(542)
Equity-based compensation			792	1,320
Gain (Loss) on sale of marketable securities			1,768	126
Amortization of finance and debt issuance costs				47
Change in assets and liabilities:
Accounts receivable				6
Funds Receivable from New Jersey net operating loss			1,641	1,090
Prepaid expenses and other current assets and other non-current assets			(500)	64
Lease liability			717	(35)
Other Assets			(73)
Accounts payable			758	(14)
Accrued expenses			1,329	(80)
Net cash used in operating activities			(10,039)	(8,220)
Cash flows from investing activities:
Proceeds from sale of marketable securities			9,082	849
Purchase of marketable securities			(1,661)	(1,611)
Purchase of property and equipment				(34)
Proceeds from sale of property and equipment			300	245
Purchase of patent and trademark rights			(96)	(444)
Net cash provided by (used in) investing activities			7,625	(995)
Cash flows from financing activities:
Payment of financing obligation				(4,732)
Financing obligation payments				(122)
Proceeds from sale of stock, net of issuance costs			80	12,917
Net cash provided by financing activities			80	8,063
Net decrease in cash and cash equivalents			(2,334)	(1,152)
Cash and cash equivalents at beginning of period			32,093	38,501	38,501
Cash and cash equivalents at end of period	$ 29,759	$ 37,349	29,759	37,349	$ 32,093
Supplemental disclosures of non-cash investing and financing cash flow information:
Operating lease-Right of Use Assets			717
Unrealized loss on marketable securities			(1,170)	(329)
Conversion of Series B preferred			$ 2	$ 7

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “the Company”,) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. The Company has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. Our flagship products are Ampligen® (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon alfa-n3). Ampligen has not been approved by the U.S. Food and Drug Administration (“FDA”) or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). Our primary present business focus involves Ampligen. Ampligen represents a double-stranded RNA being developed for globally important cancers, viral diseases and disorders of the immune system. The Company is currently proceeding primarily in four areas: ● A randomized controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients. ● Evaluate Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to check point inhibitors and other immuno oncology therapies. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or early onset treatment for existing viruses, new viruses and mutated viruses thereof. ● Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue. The Company is prioritizing activities in an order related to the stage of development, with those clinical activities in oncology, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support commercial development. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available including foreign venues and able to generate valid proof-of-concept data,. In May 2021, AIM exercised the option to re-purchase the New Brunswick manufacturing facility, pursuant to the terms of the March 2018 sale and lease-back agreement. The Company thereafter sold certain equipment and machinery that it determined to be obsolete and no longer needed for current or future manufacturing. On March 3, 2022, AIM entered into an Agreement of Sale and Purchase with Acellories, Inc. to purchase the property for an estimated $ 3.9 million, with AIM’s intention to keep some space specifically for its Alferon activity. The sale closed on November 1, 2022 for $ 3.7 million net of normal closing cost. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen API. This includes utilizing Polysciences Inc. (“Polysciences”) for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods. While AIM believes it has sufficient Ampligen API to meet current needs, it is also continually exploring new efficiencies so as to maximize its ability to fulfill future obligations. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2021 and 2020, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, building valuation, fair value of warrants, and contingency accruals.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Note 2: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 2,445,805 1,617,145

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 3: Equity-Based Compensation The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were 300,000 no Stock option for employees’ activity during the nine months ended September 30, 2022, is as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2021 1,498,798 $ 4.22 9.11 $ — Granted 150,000 0.70 9.17 — Forfeited (1,684 ) 117.6 — — Expired — — — — Outstanding September 30, 2022 1,647,114 $ 3.78 8.43 $ — Vested and expected to vest September 30, 2022 1,647,114 $ 3.78 8.43 $ — Exercisable September 30, 2022 1,542,949 $ 2.43 6.66 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 412,500 $ 4.15 5.85 $ — Granted 150,000 0.70 9.17 — Expired (1,684 ) 117.6 — — Vested (456,651 ) 1.43 — — Unvested September 30, 2022 104,165 $ 6.52 3.14 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 279,723 $ 6.12 7.93 $ — Granted 150,000 0.70 9.42 — Forfeited — — — — Expired — — — — Outstanding September 30, 2022 429,723 $ 4.10 7.96 $ — Vested and expected to vest September 30, 2022 429,723 $ 4.10 7.96 $ — Exercisable September 30, 2022 354,526 $ 4.21 8.32 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 97,831 $ 3.89 7.82 $ — Granted 150,000 0.70 9.42 — Expired — — — — Vested (172,634 ) 1.16 — — Unvested September 30, 2022 75,197 $ 3.79 8.24 $ — Stock-based compensation expense was approximately $ 792,000 1,320,000 As of September 30, 2022, and 2021, respectively, there was approximately $ 179,000 279,000

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Note 4: Marketable Securities Marketable securities consist of mutual funds. As of September 30, 2022, and December 31, 2021, it was determined that none of the marketable securities had an other-than-temporary impairment. As of September 30, 2022, and December 31, 2021, all securities were measured as Level 1 instruments under the fair value measurements standard (See Note 11: Fair Value). As of September 30, 2022, and December 31, 2021, the Company held approximately $ 6,986,000 16,175,000 Mutual Funds classified as available for sale consisted of: Schedule of Available for Sale September 30, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 6,986 $ 6,986 Totals $ 6,986 $ 6,986 Schedule of Equity Securities September 30, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (1,769 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (598 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (1,171 ) Mutual Funds classified as available for sale consisted of: December 31, 2021 (in thousands) Securities Fair Short-Term Mutual Funds $ 16,175 $ 16,175 Totals $ 16,175 $ 16,175 December 31, 2021 (in thousands) Securities Net losses recognized during the period on equity securities $ (88 ) Less: Net gains and losses recognized during the period on equity securities sold during the period — Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (88 )

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Note 5: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) September 30, 2022 December 31, 2021 Compensation $ 33 $ 1 Professional fees 1,535 169 Clinical trial expenses — 61 Other expenses 199 207 Accrued expenses $ 1,767 $ 438

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 6: Property and Equipment, net Schedule of Property and Equipment (in thousands) September 30, 2022 December 31, 2021 Land, buildings and improvements $ — $ 3,900 Furniture, fixtures, and equipment 2,353 2,353 Total property and equipment 2,353 6,253 Less: accumulated depreciation (2,235 ) (2,206 ) Property and equipment, net $ 118 $ 4,047 Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years. Depreciation expense for the nine months ending September 30, 2022 and September 30, 2021 was $ 29,000 484,000 The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $ 1,800,000 during the year ended December 31, 2021. During the period ending September 30, 2022, the Company reported assets held for sale related to the pending sale of the manufacturing facility located at 783 Jersey Avenue. On November 1, 2022, AIM completed the sale of its facility at 783 Jersey Avenue, New Brunswick, N.J., for $ 3.7 million net of normal closing cost. (See Note 11 Fair Value).

Patents

Patents	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 7: Patents Schedule of Patents, Trademark Rights (in thousands) December 31, 2020 $ 1,498 Acquisitions 592 Amortization (116 ) December 31, 2021 $ 1,974 Acquisitions 96 Amortization (57 ) September 30, 2022 $ 2,013 Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life of 17 years. Amortization of patents and trademarks for each of the next five years is as follows: Schedule of Amortization of Patents and Trademarks Period Ending December 31, (in thousands) 2022 $ 23 2023 154 2024 178 2025 199 2026 235 Thereafter 1,224 Total $ 2,013

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 8: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 250,000 8,000 1,000 The Company is authorized to issue 8,000 no 1,000 713 715 114 Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 five years 4,700,000 2 7 (b) Common Stock The Company has authorized shares of 350,000,000 8,000,000 350,000,000 On July 7, 2020, the board of directors approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 500,000 During the nine months ended September 30, 2022, the Company issued a total of 87,045 0.76 1.02 80,000 During the twelve months ended December 31, 2021, the Company issued a total of 132,238 1.16 2.35 205,000 On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 a Representative’s Warrant to purchase up to an aggregate of 266,665 . The shares of Common Stock and Warrants were sold at a combined Offering price of $ 0.90 0.99 0.899 4.99 7,200,000 15,000 On July 19, 2019, the Company entered into a new Equity Distribution Agreement (the “2019 EDA”) with Maxim Group LLC (“Maxim”), pursuant to which it could sell, from time to time, shares of its Common Stock through Maxim, as agent. The 2019 EDA replaced a prior EDA with Maxim. For the year ended December 31, 2020, the Company sold 20,444,807 53,936,615 3.5 1,888,727 5,665,731 13,301,526 3.5 465,533 The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 10 300,000 .70 ten years 613,512 1.11 1.71 ten years As of September 30, 2022, and December 31, 2021, there were 48,082,275 47,994,672

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 9 Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Recent Accounting Pronouncements
Recent Accounting Pronouncements	Note 10: Recent Accounting Pronouncements During the third quarter of 2022 accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	Note 11: Fair Value The Company is required under U.S. GAAP to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s consolidated balance sheets. The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items. The Company also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the redeemable warrants (“Warrants”) related to the Company’s April 2018, and March 2019 common stock and warrant issuance, are calculated using a Monte Carlo Simulation. While the Monte Carlo Simulation is one of a number of possible pricing models, the Company has determined it to be industry accepted and fairly presented the fair value of the Warrants. As an additional factor to determine the fair value of the Put’s liability, the occurrence probability of a Fundamental Transaction event was factored into the valuation. The Company recomputes the fair value of the Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants September 30, 2022 December 31, 2021 Underlying price per share $ 0.58 $ 0.92 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 4.06 % 0.67 % Expected holding period 1.07 1.81 Expected volatility 70 % 120 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: September 30, 2022 December 31, 2021 Underlying price per share $ 0.58 $ 0.92 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 4.12 % 0.78 % Expected holding period 1.44 2.19 Expected volatility 65 % 125 % Expected dividend yield — — Measurement input — — The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield 0.00 (v) Expected Probability of a Fundamental Transaction. a. The Company only has one product that is FDA approved but which will not be available for commercial sales for 18 months at the earliest; b. The Company flagship product is approved only in Argentina for Severely Debilitated Chronic Fatigue Syndrome patients; c. The Company may have to perform additional clinical trials for FDA approval of its flagship product; d. Industry and global market conditions continue to include uncertainty, adding risk to any transaction; e. Available capital for a potential buyer in a cash transaction continues to be limited; f. The nature of a life science company is heavily dependent on future funding and high costs, including research & development; g. The Company has minimal revenue streams which could be insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and h. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0 (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction 100 (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., using historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The Company applies FASB ASC 820 that defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. The guidance does not impose any new requirements around which assets and liabilities are to be measured at fair value, and instead applies to asset and liability balances required or permitted to be measured at fair value under existing accounting pronouncements. The Company measures its warrant liability for those warrants with a cash settlement feature at fair value. FASB ASC 820-10-35-37 establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels: ● Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes certain U.S. and government agency debt and equity securities that are traded in an active market. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2022, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing these warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 6,986 $ 6,986 $ — $ — Liabilities: Redeemable warrants $ — — — $ — (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,175 $ 16,175 $ — $ — Liabilities: Redeemable warrants $ 35 — — $ 35 The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2021 $ 35 Fair value adjustment (35 ) Balance at September 30, 2022 $ — The table below presents the balances of assets and liabilities measured at fair value on a nonrecurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis (in thousands) Total Level 1 Level 2 Level 3 Total Gains (Losses) Assets: Long lived assets held and used (a) $ 3,900 $ — $ — $ 3,900 $ (1,800 ) (a) In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000 300,000

Financing Obligation Arising fr

Financing Obligation Arising from Sale Leaseback Transaction	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Financing Obligation Arising from Sale Leaseback Transaction	Note 12: Financing Obligation Arising from Sale Leaseback Transaction On March 16, 2018, the Company sold land and a building for $ 4,080,000 lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments would increase 2.5% per year for the next three years through March 31, 2023, and the lease payments would increase 3% for the remaining five years 73,314 five years 17.05 125 On May 13, 2021, the Company completed its repurchase of the property for cash of $ 4,732,637 Interest expense relating to this financing agreement was $ 0 67,000

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 13: Leases The Company leases office and storage space, and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 Leases The Company’s lease terms may include options to extend or terminate the lease. The Company exercises judgment to determine the term of those leases when extension or termination options are present and include such options in the calculation of the lease term when it is reasonably certain that it will exercise those options. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion would be recognized as variable lease expenses, when incurred. Variable payments made to third parties for these, or similar costs, such as utilities, are not included in the calculation of lease payments. At lease commencement, lease-related assets and liabilities are measured at the present value of future lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company exercises judgment in determining the incremental borrowing rate based on the information available when the lease commences to measure the present value of future payments. Operating leases are included in other assets, current operating lease obligations, and operating lease obligations (less current portion) on the Company’s consolidated balance sheet. Short term leases with an initial term of 12 months or less are not presented on the balance sheet with expense recognized as incurred. The Company entered into a Lease Agreement for a term of five years September 14, 2020 1,415 On June 13, 2018, the Company entered into a Lease Agreement for a term of six years July 1, 2018 3,000 3 2,100 2,785 On May 1, 2019, the Company entered into a Lease Agreement for a term of three years May 1, 2019 3,000 2,500 2,850 one-year May 1, 2023 On February 17, 2022, the Company entered into a Lease Agreement for a term of two years March 1, 2022 322 On June 16, 2022, the Company entered into a Lease Agreement for a term of five years July 1, 2022 5,210 3 15,630 18,118 The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 11 5 2.67 2.72 The Company has determined that the incremental borrowing rate is 10 Future minimum payments as of September 30, 2022, are as follows: Schedule of Operating lease Future Payments Period December 31, (in thousands) 2022 $ 46 2023 187 2024 183 2025 180 2026 185 Thereafter 171 Less imputed interest (86 ) Total $ 866 As of September 30, 2022, and December 31, 2021, the balance of the right of use assets was $ 866,000 149,000 866,000 149,000 75,000 39,000 8,000

Research, Consulting and Supply

Research, Consulting and Supply Agreements	9 Months Ended
	Sep. 30, 2022
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 14: Research, Consulting and Supply Agreements In January 2021, the Company entered into a Sponsor Agreement with the Centre for Human Drug Research (“CHDR”) for a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as a potential intranasal therapy. The Company has paid CHDR approximately $ 1,066,000 In April 2021, the Company approved a proposal from Polysciences for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods at Polysciences’ Warrington, PA location to enhance our capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences to negotiate and finalize both a Service Agreement and a Quality Agreement. For the year ended December 31, 2021, the Company has incurred an expense and paid Polysciences approximately $ 250,000 103,000 In April 2022, AIM executed a work order with Amarex Clinical Research LLC (“Amarex”), our contract research organization, pursuant to which Amarex will manage a Phase 2 clinical trial in advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that the study will cost approximately $ 8.2 1.0 4.6 On June 13, 2022, AIM executed a work order with Amarex, pursuant to which Amarex will manage a Phase 2 trial in patients with Post-COVID Conditions. It is planned that the study will be conducted at up to 10 sites in the United States. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $ 4.4 125,470 2.4 In December 2020, AIM added Pharmaceutics International Inc. (“Pii”) as a “Fill & Finish” provider to enhance its capacity to produce Ampligen. This addition amplifies AIM’s manufacturing capability by providing redundancy and cost savings. The contracts augment our active and in-process fill and finish capacity. For the period ended December 31, 2021, the Company has incurred an expense and paid Pii approximately $ 89,000 259,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 15: Subsequent Events On October 5, 2022, the Delaware Court of Chancery held a hearing regarding a motion to require the AIM Board of Directors to accept the Jorgl Group’s director nominations and include the group’s nominees on a universal proxy card for the 2022 Annual Meeting of Stockholders. On October 28, 2022, the court denied Jorgl’s motion. The Jorgl Group announced on November 2, 2022, that it did not intend to appeal the decision. On October 12, 2022, the Company announced that its Investigational New Drug (IND) application filed with the FDA was granted clearance to proceed and therefore the Company could initiate a Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions (“AMP-518”). On November 1, 2022, AIM completed the sale of its facility at 783 Jersey Avenue, New Brunswick, N.J., for $ 3.7 million net of normal closing cost . In November 2022, AIM received notice that the FDA had granted Orphan Drug Designation to Ampligen for the treatment of Ebola virus disease.

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2021 1,498,798 $ 4.22 9.11 $ — Granted 150,000 0.70 9.17 — Forfeited (1,684 ) 117.6 — — Expired — — — — Outstanding September 30, 2022 1,647,114 $ 3.78 8.43 $ — Vested and expected to vest September 30, 2022 1,647,114 $ 3.78 8.43 $ — Exercisable September 30, 2022 1,542,949 $ 2.43 6.66 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 412,500 $ 4.15 5.85 $ — Granted 150,000 0.70 9.17 — Expired (1,684 ) 117.6 — — Vested (456,651 ) 1.43 — — Unvested September 30, 2022 104,165 $ 6.52 3.14 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 279,723 $ 6.12 7.93 $ — Granted 150,000 0.70 9.42 — Forfeited — — — — Expired — — — — Outstanding September 30, 2022 429,723 $ 4.10 7.96 $ — Vested and expected to vest September 30, 2022 429,723 $ 4.10 7.96 $ — Exercisable September 30, 2022 354,526 $ 4.21 8.32 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 97,831 $ 3.89 7.82 $ — Granted 150,000 0.70 9.42 — Expired — — — — Vested (172,634 ) 1.16 — — Unvested September 30, 2022 75,197 $ 3.79 8.24 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Available for Sale	Mutual Funds classified as available for sale consisted of: Schedule of Available for Sale September 30, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 6,986 $ 6,986 Totals $ 6,986 $ 6,986 December 31, 2021 (in thousands) Securities Fair Short-Term Mutual Funds $ 16,175 $ 16,175 Totals $ 16,175 $ 16,175
Schedule of Equity Securities	Schedule of Equity Securities September 30, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (1,769 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (598 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (1,171 ) (in thousands) Securities Net losses recognized during the period on equity securities $ (88 ) Less: Net gains and losses recognized during the period on equity securities sold during the period — Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (88 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses (in thousands) September 30, 2022 December 31, 2021 Compensation $ 33 $ 1 Professional fees 1,535 169 Clinical trial expenses — 61 Other expenses 199 207 Accrued expenses $ 1,767 $ 438

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment (in thousands) September 30, 2022 December 31, 2021 Land, buildings and improvements $ — $ 3,900 Furniture, fixtures, and equipment 2,353 2,353 Total property and equipment 2,353 6,253 Less: accumulated depreciation (2,235 ) (2,206 ) Property and equipment, net $ 118 $ 4,047

Patents (Tables)

Patents (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents, Trademark Rights	Schedule of Patents, Trademark Rights (in thousands) December 31, 2020 $ 1,498 Acquisitions 592 Amortization (116 ) December 31, 2021 $ 1,974 Acquisitions 96 Amortization (57 ) September 30, 2022 $ 2,013
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years is as follows: Schedule of Amortization of Patents and Trademarks Period Ending December 31, (in thousands) 2022 $ 23 2023 154 2024 178 2025 199 2026 235 Thereafter 1,224 Total $ 2,013

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assumptions to Estimate Fair Value of Warrants	The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants September 30, 2022 December 31, 2021 Underlying price per share $ 0.58 $ 0.92 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 4.06 % 0.67 % Expected holding period 1.07 1.81 Expected volatility 70 % 120 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: September 30, 2022 December 31, 2021 Underlying price per share $ 0.58 $ 0.92 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 4.12 % 0.78 % Expected holding period 1.44 2.19 Expected volatility 65 % 125 % Expected dividend yield — — Measurement input — —
Schedule of Range of Probabilities	Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 6,986 $ 6,986 $ — $ — Liabilities: Redeemable warrants $ — — — $ — (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,175 $ 16,175 $ — $ — Liabilities: Redeemable warrants $ 35 — — $ 35
Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2021 $ 35 Fair value adjustment (35 ) Balance at September 30, 2022 $ —
Schedule of Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a nonrecurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis (in thousands) Total Level 1 Level 2 Level 3 Total Gains (Losses) Assets: Long lived assets held and used (a) $ 3,900 $ — $ — $ 3,900 $ (1,800 ) (a) In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000 300,000

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule of Operating lease Future Payments	Future minimum payments as of September 30, 2022, are as follows: Schedule of Operating lease Future Payments Period December 31, (in thousands) 2022 $ 46 2023 187 2024 183 2025 180 2026 185 Thereafter 171 Less imputed interest (86 ) Total $ 866

Business and Basis of Present_2

Business and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands			9 Months Ended
	Nov. 01, 2022	Mar. 03, 2021	Sep. 30, 2022	Sep. 30, 2021
Purchase of property				$ 34
Proceeds from sale of property			$ 300	$ 245
Subsequent Event [Member]
Proceeds from sale of property	$ 3,700
Acellories Inc [Member]
Purchase of property		$ 3,900

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	2,445,805	1,617,145

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, Beginning	1,498,798
Weighted average exercise price, Beginning	$ 4.22
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 5 months 4 days	9 years 1 month 9 days
Aggregate Intrinsic Value, Beginning
Number of options outstanding, Granted	150,000
Weighted average exercise price, Granted	$ 0.70
Weighted Average Remaining Contractual Term (Years), Granted	9 years 2 months 1 day
Number of Options, Forfeited	(1,684)
Weighted Average Exercise Price, Forfeited	$ 117.6
Number of Options, Expired
Weighted Average Exercise Price, Expired
Number of options outstanding, Ending	1,647,114	1,498,798
Weighted Average Exercise Price Outstanding, End of Period	$ 3.78	$ 4.22
Aggregate Intrinsic Value, Ending
Number of options outstanding, Vested and expected	1,647,114
Vested and expected to vest, Weighted average exercise price	$ 3.78
Weighted Average Remaining Contractual Term (Years), Vested and expected	8 years 5 months 4 days
Aggregate Intrinsic Value, Vested and expected
Number of options outstanding, Exercisable	1,542,949
Exercisable, Weighted average exercise price	$ 2.43
Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 7 months 28 days
Aggregate Intrinsic Value, Exercisable
Number of Options, Forfeited	1,684
Number of Options, Expired
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, Beginning	279,723
Weighted average exercise price, Beginning	$ 6.12
Weighted Average Remaining Contracted Term (years) Outstanding	7 years 11 months 15 days	7 years 11 months 4 days
Aggregate Intrinsic Value, Beginning
Number of options outstanding, Granted	150,000
Weighted average exercise price, Granted	$ 0.70
Weighted Average Remaining Contractual Term (Years), Granted	9 years 5 months 1 day
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited
Number of Options, Expired
Weighted Average Exercise Price, Expired
Number of options outstanding, Ending	429,723	279,723
Weighted Average Exercise Price Outstanding, End of Period	$ 4.10	$ 6.12
Aggregate Intrinsic Value, Ending
Number of options outstanding, Vested and expected	429,723
Vested and expected to vest, Weighted average exercise price	$ 4.10
Weighted Average Remaining Contractual Term (Years), Vested and expected	7 years 11 months 15 days
Aggregate Intrinsic Value, Vested and expected
Number of options outstanding, Exercisable	354,526
Exercisable, Weighted average exercise price	$ 4.21
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 3 months 25 days
Aggregate Intrinsic Value, Exercisable
Number of Options, Forfeited
Number of Options, Expired

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Granted	300,000	0
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Beginning	412,500
Weighted Average Exercise Price, Beginning	$ 4.15
Weighted Average Remaining Contractual Term (Years), Ending	5 years 10 months 6 days
Aggregate Intrinsic Value, Beginning
Number of Options, Granted	150,000
Weighted Average Exercise Price, Granted	$ 0.70
Weighted Average Remaining Contractual Term (Years), Granted	9 years 2 months 1 day
Number of Options, Expired	(1,684)
Weighted Average Exercise Price, Expired	$ 117.6
Number of Options, Vested	(456,651)
Weighted Average Exercise Price, Vested	$ 1.43
Number of Options, Ending	104,165		412,500
Weighted Average Exercise Price, Ending	$ 6.52		$ 4.15
Weighted Average Remaining Contractual Term (years) Unvested, Ending of Period	3 years 1 month 20 days
Aggregate Intrinsic Value, Ending
Number of Options, Expired	1,684
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Beginning	97,831
Weighted Average Exercise Price, Beginning	$ 3.89
Weighted Average Remaining Contractual Term (Years), Ending	8 years 2 months 26 days		7 years 9 months 25 days
Aggregate Intrinsic Value, Beginning
Number of Options, Granted	150,000
Weighted Average Exercise Price, Granted	$ 0.70
Weighted Average Remaining Contractual Term (Years), Granted	9 years 5 months 1 day
Number of Options, Expired
Weighted Average Exercise Price, Expired
Number of Options, Vested	(172,634)
Weighted Average Exercise Price, Vested	$ 1.16
Number of Options, Ending	75,197		97,831
Weighted Average Exercise Price, Ending	$ 3.79		$ 3.89
Aggregate Intrinsic Value, Ending
Number of Options, Expired

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Options, granted	300,000	0
Share based compensation expense	$ 792	$ 1,320
Unrecognized stock-based compensation cost	$ 179	$ 279

Schedule of Available for Sale

Schedule of Available for Sale (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Fair Value	$ 6,986	$ 16,175
Short-Term Investments	6,986	16,175
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	6,986	16,175
Short-Term Investments	$ 6,986	$ 16,175

Schedule of Equity Securities (

Schedule of Equity Securities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Net losses recognized during the period on equity securities	$ (1,769)	$ (88)
Less: Net gains and losses recognized during the period on equity securities sold during the period	(598)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	$ (1,171)	$ (88)

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable securities	$ 6,986	$ 16,175

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation	$ 33	$ 1
Professional fees	1,535	169
Clinical trial expenses		61
Other expenses	199	207
Accrued expenses	$ 1,767	$ 438

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,353	$ 6,253
Less: accumulated depreciation	(2,235)	(2,206)
Property and equipment, net	118	4,047
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		3,900
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,353	$ 2,353

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	Nov. 01, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Depreciation		$ 29	$ 484
Asset Impairment Charges				$ 1,800
Proceeds from Sale of Property, Plant, and Equipment		$ 300	$ 245
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Sale of Property, Plant, and Equipment	$ 3,700

Schedule of Patents, Trademark

Schedule of Patents, Trademark Rights (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 1,974	$ 1,498	$ 1,498
Acquisitions	96		592
Amortization	(57)	$ (97)	(116)
Ending balance	$ 2,013		$ 1,974

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 23
2023	154
2024	178
2025	199
2026	235
Thereafter	1,224
Total	$ 2,013	$ 1,974	$ 1,498

Patents (Details Narrative)

Patents (Details Narrative)	9 Months Ended
	Sep. 30, 2022
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	17 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				3 Months Ended						9 Months Ended		12 Months Ended
	Jul. 07, 2020	Sep. 27, 2019	Sep. 12, 2018	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 16, 2018
Class of Stock [Line Items]
Preferred stock, shares authorized				5,000,000						5,000,000
Preferred stock stated value				$ 0.01						$ 0.01
Warrant exercise price														$ 17.05
Warrants and rights outstanding term														5 years
Common stock, shares authorized				350,000,000			350,000,000			350,000,000		350,000,000
Common stock specific limitations and restrictions on usage				8,000,000						8,000,000
Common stock shares issued, value				$ 25,000	$ 55,000			$ 30,000	$ 12,887,000
Warrants issued														73,314
Proceeds from Issuance or Sale of Equity										$ 80,000	$ 12,917,000
Warrant outstanding				15,000						15,000
Number of options granted										300,000	0
Common stock, shares outstanding				48,082,275			47,994,672			48,082,275		47,994,672
Director [Member]
Class of Stock [Line Items]
Option vested years			10 years
2018 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of stock is reserved for potential issuance			7,000,000
2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Number of options granted						300,000	613,512
Option exercise price per share						$ 0.70
Expiration period						10 years	10 years
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Shares issued price per share		$ 0.899
Percentage of outstanding stock		4.99%
Warrant [Member]
Class of Stock [Line Items]
Warrant exercise price		$ 0.99
Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction		1,740,550
Warrants issued		7,148,310
Proceeds from Issuance or Sale of Equity		$ 7,200,000
Alliance Global Partners, LLC [Member] | Warrants [Member]
Class of Stock [Line Items]
Number of warrant to purchase shares of common stock		8,888,860
Alliance Global Partners, LLC [Member] | Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Shares issued price per share		$ 0.90
Maxim Group LLC [Member] | Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity												$ 13,301,526	$ 53,936,615
Sale of stock, Number of shares issued												5,665,731	20,444,807
Shares sales fee percentage							3.50%					3.50%	3.50%
Underwriting fee amount.												$ 465,533	$ 1,888,727
Minimum [Member] | 2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Option exercise price per share							$ 1.11
Maximum [Member] | 2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Option exercise price per share							1.71
Maximum [Member] | Alliance Global Partners, LLC [Member] | Representative Warrants [Member]
Class of Stock [Line Items]
Number of warrant to purchase shares of common stock		266,665
Directors, Officers and Employees [Member]
Class of Stock [Line Items]
Common stock shares issued, value	$ 500,000
Rights [Member]
Class of Stock [Line Items]
Warrant exercise price				$ 1,000						$ 1,000
Proceeds from warrants										$ 4,700,000
Warrant [Member]
Class of Stock [Line Items]
Warrant exercise price				$ 8.80						$ 8.80
Warrants and rights outstanding term				5 years						5 years
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized				250,000						250,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized				8,000						8,000
Preferred stock stated value				$ 1,000			$ 1,000			$ 1,000		$ 1,000
Preferred Stock, no par value				$ 0						$ 0
Preferred Stock, Shares Outstanding				713			715			713		715
Conversion of common stock										2	7
Series B Convertible Preferred Stock [Member] | Rights [Member]
Class of Stock [Line Items]
Preferred stock face value				$ 1,000						$ 1,000
Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares to be issued on conversion				114						114
Common Stock [Member]
Class of Stock [Line Items]
Common stock shares issued, value										$ 80,000		$ 205,000
Number of shares issued upon transaction										87,045		132,238
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares issued price per share				$ 0.76			$ 1.16			$ 0.76		$ 1.16
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Shares issued price per share				$ 1.02			$ 2.35			$ 1.02		$ 2.35

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate Fair Value of Warrants (Details)	Sep. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares	Mar. 16, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term			5 years
April 2018 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.58	$ 0.92
April 2018 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	17.16	17.16
April 2018 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	4.06	0.67
April 2018 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 25 days	1 year 9 months 21 days
April 2018 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	70	120
April 2018 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input
March 2019 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.58	$ 0.92
March 2019 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	8.80	8.80
March 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	4.12	0.78
March 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 5 months 8 days	2 years 2 months 8 days
March 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	65	125
March 2019 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input

Schedule of Range of Probabilit

Schedule of Range of Probabilities (Details)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	0.50%
Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	1%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 6,986	$ 16,175
Redeemable warrants		35
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	6,986	16,175
Redeemable warrants
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants		$ 35

Schedule of Changes in Level 3

Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Details) - Redeemable Warrants [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Balance at beginning	$ 35
Fair value adjustments	(35)
Balance at ending

Schedule of Assets and Liabil_2

Schedule of Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)	[1]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment	$ 3,900
Total Gains (Losses)	(1,800)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment	$ 3,900
[1]In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000 300,000

Schedule of Assets and Liabil_3

Schedule of Assets and Liabilities Measured at Fair Value on a NonRecurring Basis (Details) (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property plant and equipment collections		$ 3,900,000
Impairment charges		1,800,000
Deposit received	$ 300,000
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Long lived assets held for sale carrying amount		$ 5,700,000

Fair Value (Details Narrative)

Fair Value (Details Narrative)	9 Months Ended
	Sep. 30, 2022 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%
Floor rate used as proxy for future volatility percentage	100%
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, per share	$ 0

Financing Obligation Arising _2

Financing Obligation Arising from Sale Leaseback Transaction (Details Narrative) - USD ($)			9 Months Ended
	May 13, 2021	Mar. 16, 2018	Sep. 30, 2022	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of buildings		$ 4,080,000
Lease and property agreement description		lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments would increase 2.5% per year for the next three years through March 31, 2023, and the lease payments would increase 3% for the remaining five years through March 31, 2028
Warrants term		5 years
Warrant to purchase of common stock		73,314
Warrant exercise price per share		$ 17.05
Warrant closing price, percentage		125%
Repurchase of property	$ 4,732,637
Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest expense			$ 0	$ 67,000

Schedule of Operating lease Fut

Schedule of Operating lease Future Payments (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Leases
2022	$ 46,000
2023	187,000
2024	183,000
2025	180,000
2026	185,000
Thereafter	171,000
Less imputed interest	(86,000)
Total	$ 866,000	$ 149,000

Leases (Details Narrative)

Leases (Details Narrative)							9 Months Ended		12 Months Ended
	Oct. 05, 2022 USD ($)	Jun. 16, 2022 USD ($) ft²	Feb. 17, 2022 USD ($)	Sep. 14, 2020 USD ($)	May 01, 2019 USD ($) ft²	Jun. 13, 2018 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Rent expenses							$ 75,000	$ 39,000
Weighted average remaining term							2 years 8 months 1 day		2 years 8 months 19 days
Incremental borrowing rate							0.10		0.10
Right of use asset							$ 866,000		$ 149,000
Operating lease liability							866,000		$ 149,000
Short term lease rent expense							$ 8,000	$ 8,000
Lease Agreement [Member]
Lease agreement term	1 year	5 years			3 years
Lease commenced date	May 01, 2023	Jul. 01, 2022			May 01, 2019
Base rent per month					$ 2,500
Rentable area | ft²		5,210			3,000
Percentage of base rent		3%
Rent expenses	$ 2,850
Lease Agreement [Member] | First Year [Member]
Base rent per month		$ 15,630
Lease Agreement [Member] | Fifth Year [Member]
Base rent per month		$ 18,118
Lease Agreement [Member] | Fraser Advanced Information Systems [Member]
Lease agreement term				5 years
Lease commenced date				Sep. 14, 2020
Base rent per month				$ 1,415
Lease Agreement [Member] | SML FL Holdings LLC [Member]
Lease agreement term						6 years
Lease commenced date						Jul. 01, 2018
Rentable area | ft²						3,000
Percentage of base rent						3%
Lease Agreement [Member] | SML FL Holdings LLC [Member] | First Year [Member]
Base rent per month						$ 2,100
Lease Agreement [Member] | SML FL Holdings LLC [Member] | Sixth Year [Member]
Base rent per month						$ 2,785
Lease Agreement [Member] | Canon Copier [Member]
Lease agreement term			2 years
Lease commenced date			Mar. 01, 2022
Base rent per month			$ 322
Minimum [Member]
Operating lease term							1 year
Operating lease, remaining lease term							11 months
Maximum [Member]
Operating lease term							5 years
Operating lease, remaining lease term							5 years

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 13, 2022	Apr. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Research and development expense			$ 1,372,000	$ 2,006,000	$ 4,883,000	$ 4,749,000
Centre for Human Drug Research [Member]
Research and consulting					1,066,000
Polysciences Inc [Member]
Research and consulting					103,000		$ 250,000
Amarex Clinical Research LLC [Member]
Research and development expense		$ 8,200,000
Research and development expense	$ 4,400,000	$ 1,000,000
Estimated lives		4 years 7 months 6 days
Development cost	125,470
Invigilators cost	$ 2,400,000
Pharmaceutics International, Inc [Member]
Research and development expense					$ 259,000		$ 89,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands		9 Months Ended
	Nov. 01, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Proceeds from Sale of Property, Plant, and Equipment		$ 300	$ 245
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Sale of Property, Plant, and Equipment	$ 3,700